CrystalGenomics Nominated for the Scrip Award in the Category of Best Company in an Emerging Market
Published: Sep 14, 2010
SEOUL, South Korea, Sept. 14 /PRNewswire/ -- CrystalGenomics, Inc. (www.cgxinc.com), a leading biopharmaceutical company developing novel therapeutics announced today that it has been nominated for this year's Scrip Awards (www.scripawards.com) in the category of Best Company in an Emerging Market. The winner will be announced at the 6th Annual Scrip Award ceremony on November 4th in London.
The Scrip Awards are one of the industry's most prestigious contested awards to highlight the achievements of pharmaceutical, biotech and clinical research companies throughout the year and organized by Scrip Publishing with a distinguished international panel of judges. This year's finalists were evaluated by this judging panel consisting of 19 industry experts who has extensively examined the accomplishments of each of the candidates.
Best Company in an Emerging Market Award is designed to recognize the achievements of drug development companies in areas outside the industry's traditional borders and therefore, includes emerging market territories of Asia, Central and Eastern Europe, Central and South America, the Middle East and Africa. The criteria on which the judges based their decision included growth in sales and profits, signing of important deals, success in introducing new products to the market, quality of its new drug pipeline, and ability to make operational improvement.
One of CrystalGenomics' most significant achievements during this year was the signing of the Research Collaboration deal with AstraZeneca for novel anti-infective therapeutics. This was the first time for AstraZeneca to form this type of alliance with a Korea based company in the field of anti-infectives and it had indirectly validated CrystalGenomics' discovery capabilities and increased its visibility outside of Korea. CrystalGenomics has also made huge strides in advancement of its drug pipeline during this year as it had reached few notable clinical milestones with its antibiotic and oncology programs.
President & CEO of CrystalGenomics, Joong Myung Cho said, "Even with a record number of entries this year for the Scrip Awards, we are truly honored to be nominated as one of the finalists. We are delighted to be recognized for the tremendous year that we had and plan to raise the bar even higher as we continue to strive to reach new heights."
SOURCE CrystalGenomics, Inc.